X4 PHARMACEUTICALS XFOR 深 沪
等待开盘 10-11 09:30:00 美东时间
3.09
-0.340
-9.91%
华盛通- 最 高3.42
- 今 开3.30
- 成交量 58.08万股
- 最 低 3.07
- 昨 收 3.43
- 总市值 3525.20万
- 52周最高 26.829
- 市盈率 静 --
- 换手率 0.01%
- 52周最低 1.35
- 委 比 -93.10%
- 总股本 1140.84万
- 历史最高 717.90
- 量 比 1.42
- 振 幅 10.20%
- 历史最低 3.07
- 每 手 1
- 风险率 6.44%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多X4 Pharmaceuticals to reduce 50% of workforce
X4 Pharmaceuticals (NASDAQ:XFOR) has announced a restructuring program to align resources with its long-term strategy to complete the Phase 3 4WARD trial for chronic neutropenia. The plan includes cut...
09-17 19:33
X4 Pharmaceuticals Announces Major Strategic Restructuring
X4 Pharmaceuticals ( ($XFOR) ) has provided an update. On September 17, 2025, X...
09-17 19:29
X4 Pharmaceuticals Announces Strategic Restructuring With 50% Workforce Reduction Expected To Deliver $13M Annualized Cost Savings
Organizational restructuring including a 50% reduction in workforce that is anticipated to result in annualized cost savings of approximately $13MJohn Volpone appointed Chief Operating Officer, in addition to his current
09-17 19:12
X4 Pharmaceuticals Announces Restructuring of Business Operations Designed to Drive Long-Term Value Creation
X4 Pharmaceuticals announced a 50% workforce reduction, expected to save $13M annually, as part of strategic restructuring to focus on completing the 4WARD Phase 3 trial for chronic neutropenia. John Volpone was appointed Chief Operating Officer alongside his role as President, while Dr. Adam Craig will oversee clinical development. Natasha Thoren, Mary DiBiase, and Mark Baldry are leaving, and Dr. Christophe Arbet-Engels is resigning for persona...
09-17 11:00
Stifel Maintains Buy on X4 Pharmaceuticals, Lowers Price Target to $9
Stifel analyst Stephen Willey maintains X4 Pharmaceuticals (NASDAQ:XFOR) with a Buy and lowers the price target from $30 to $9.
08-29 21:13
X4 Pharmaceuticals Announces Board Resignations and Appointments
The latest announcement is out from X4 Pharmaceuticals ( ($XFOR) ). On August 2...
08-25 20:27
X4 Pharmaceuticals Announces Closing of Upsized $85 Million Private Placement
X4 Pharmaceuticals completed a $85 million private placement of shares and warrants, up from the initial $60 million target, to include an investor with a pre-existing investment right. The financing was led by Coastlands Capital, supported by existing and new life sciences investors. Proceeds will fund the continued development of mavorixafor for chronic neutropenia and WHIM syndrome commercialization.
08-13 11:00
X4 Pharmaceuticals secures $60M PIPE financing
X4 Pharmaceuticals (NASDAQ:XFOR) has entered into a $60 million PIPE financing deal, expected to close around August 13, 2025, pending customary conditions. The company will issue 11,040,776 shares at...
08-12 21:49
X4 Pharmaceuticals Announced Private Placement In Public Equity Financing Of Approximately $60M
$60 million PIPE financing led by Coastlands Capital, Bain Capital Life Sciences and New Enterprise AssociatesNewly appointed board and management team includes Dr. Adam Craig as Executive Chairman, John Volpone as
08-12 19:14
X4 Pharmaceuticals Announces $60 Million Equity Financing with Concurrent Changes in Management and Board Leadership
X4 Pharmaceuticals announced a $60 million PIPE financing led by Coastlands Capital, Bain Capital Life Sciences, and NEA. The company also appointed Dr. Adam Craig as Executive Chairman, John Volpone as President, and David Kirske as CFO, all former CTI BioPharma executives. New leadership aims to unlock the commercial potential of mavorixafor. Proceeds will support further development and commercialization efforts.
08-12 11:00
